Abstract
Purpose
The glycoprotein macrophage migration inhibitory factor (MIF) is a cytokine that has been shown to promote tumor progression and tumor immune escape in ovarian cancer. The present study investigates MIF in uterine cervical cancer.
Methods
Eighty surgical biopsies (32 cervical dysplasias, 23 in situ carcinomas and 25 invasive carcinomas) of uterine cervical tissue were evaluated immunohistochemically for MIF expression. In uterine cervical cancer cell lines SiHa and CaSki and their respective supernatants, MIF protein expression was analyzed by Western blotting, enzyme-linked immunosorbent assay (ELISA) and reverse transcriptase polymerase chain reaction (RT-PCR).
Results
Immunohistochemical analysis shows that MIF is clearly overexpressed on the protein level in invasive cervical cancer compared to cervical dysplasias. MIF overexpression was confirmed by RT-PCR in surgical biopsies of invasive cervical cancer. Western blotting reveals that the MIF protein is overexpressed in SiHA und CaSki cervical cancer cell lines, whereas the ELISA reveals that cervical cancer cells secrete MIF.
Conclusions
MIF has been shown to promote tumor immune escape mechanisms in other cancer entities, which makes it an interesting target for cancer therapy, given the known significance of immune mechanisms for uterine cervical cancer. The overexpression of MIF on the protein and mRNA level, as well as its secretion by cervical cancer cells points to a critical role of the protein for the pathogenesis of uterine cervical cancer.
Similar content being viewed by others
References
Agarwal R, Whang DH, Alvero AB Visintin I, Lai Y, Segal EA, Schwartz P, Ward D, Rutherford T, Mor G (2007) Macrophage migration inhibitory factor expression in ovarian cancer. Am J Obstet Gynecol 196:348.e1-e5
Bartfeld H, Atoynatan T (1971) Activity and properties of macrophage migration inhibitory factor produced by mixed lymphocyte cultures. Nat New Biol 230(16):246–247
Binsky I, Haran M, Starlets D, Gore Y, Lantner F, Harpaz N, Leng L, Goldenberg DM, Shvidel L, Berrebi A, Bucala R, Shachar I (2007) IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci USA 104:13408–13413
Camlica H, Duranyildiz D, Oguz H, Oral EN, Yasasever V (2008) The diagnostic value of macrophage migration inhibitory factor (MIF) in gastric cancer. Pathol Oncol Res 14:79–83
Coleman AM, Rendon BE, Zhao M, Qian MW, Bucala R, Xin D, Mitchell RA (2008) Cooperative regulation of non-small cell lung carcinoma angiogenic potential by macrophage migration inhibitory factor and its homolog, d-dopachrome tautomerase. J Immunol 181:2330–2337
Fingerle-Rowson G, Petrenko O, Metz CN, Forsthuber TG, Mitchell R, Huss R, Moll U, Müller W, Bucala R (2003) The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci USA 100:9354–9359
Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR (2005) Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 175:1197–1205
James RM, Cruickshank ME, Siddiqui N (2008) Guideline Development Group. Management of cervical cancer: summary of SIGN guidelines. BMJ 336:41–43
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics. CA Cancer J Clin 58:71–96
Krockenberger M, Dombrowski Y, Weidler C, Ossadnik M, Hönig A, Häusler S, Voigt H, Becker JC, Leng L, Steinle A, Weller M, Bucala R, Dietl J, Wischhusen J (2008) Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol 180:7338–7348
Lee H, Rhee H, Kang HJ, Kim HS, Min BS, Kim NK, Kim H (2008) Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas. Am J Clin Pathol 129:772–779
Long HJ 3rd (2007) Management of metastatic cervical cancer: review of the literature. J Clin Oncol 25:2966–2974
Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, Fingerle-Rowson G, Bucala R, Lüscher B, Bernhagen J (2007) Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 26:5046–5059
Meyer-Siegler KL, Vera PL, Iczkowski KA, Bifulco C, Lee A, Gregersen PK, Leng L, Bucala R (2007) Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes Immun 8:646–652
Mitchell RA (2004) Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal 16:13–19
Muramaki M, Miyake H, Yamada Y, Hara I (2006) Clinical utility of serum macrophage migration inhibitory factor in men with prostate cancer as a novel biomarker of detection and disease progression. Oncol Rep 15:253–257
Nedergaard BS, Ladekarl M, Nyengaard JR, Nielsen K (2008) A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years. Gynecol Oncol 108:106–111
Papageorgiou PS, Henley WL, Glade PR (1972) Production and characterization of migration inhibitory factor(s) (MIF) of established lymphoid and non-lymphoid cell lines. J Immunol 108:494–504
Petrenko O, Moll UM (2005) Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathway. Mol Cell 17:225–236
Ren Y, Tsui HT, Poon RT, Ng IO, Li Z, Chen Y, Jiang G, Lau C, Yu WC, Bacher M, Fan ST (2003) Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer 107:22–29
Rendon BE, Roger T, Teneng I, Zhao M, Al-Abed Y, Calandra T, Mitchell RA (2007) Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J Biol Chem 12:282(41):29910–29918
Sun B, Nishihira J, Yoshiki T, Kondo M, Sato Y, Sasaki F, Todo S (2005) Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway. Clin Cancer Res 11:1050–1058
Textor S, Dürst M, Jansen L, Accardi R, Tommasino M, Trunk MJ, Porgador A, Watzl C, Gissmann L, Cerwenka A (2008) Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer 123:2343–2353
Wilson JM, Coletta PL, Cuthbert RJ, Scott N, MacLennan K, Hawcroft G, Leng L, Lubetsky JB, Jin KK, Lolis E, Medina F, Brieva JA, Poulsom R, Markham AF, Bucala R, Hull MA (2005) Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology 129:1485–1503
Winner M, Meier J, Zierow S, Rendon BE, Crichlow GV, Riggs R, Bucala R, Leng L, Smith N, Lolis E, Trent JO, Mitchell RA (2008) A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. Cancer Res 68(18):7253–7257
Xu X, Wang B, Ye C, Yao C, Lin Y, Huang X, Zhang Y, Wang S (2008) Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett 261:147–157
Yu DS, Hsieh DS, Chang SY (2006a) Increasing expression of GST-pi MIF, and ID1 genes in chemoresistant prostate cancer cells. Arch Androl 52:275–281
Yu DS, Lin JC, Hsieh DS, Chang SY, Lee CF (2006b) Modulation of MDR-1 gene by MIF and GSTpi with drug resistance generation in hormone independent prostate cancer. Arch Androl 52:283–291
Zhou Q, Yan X, Gershan J, RJ Orentas, BD Johnson (2008) Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo. J Immunol 181:1877–1886
Conflict of interest statement
There is no conflict of interest regarding this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Krockenberger, M., Engel, J.B., Kolb, J. et al. Macrophage migration inhibitory factor expression in cervical cancer. J Cancer Res Clin Oncol 136, 651–657 (2010). https://doi.org/10.1007/s00432-009-0702-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-009-0702-5